US 11845752
Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B
granted A61KA61K45/06
Quick answer
US patent 11845752 (Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B) held by Aligos Therapeutics, Inc. expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Aligos Therapeutics, Inc.
- Grant date
- Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 21
- CPC classes
- A61K, A61K45/06